FRANCE: Deinove, a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, has announced a collaboration with Dow for the joint development of a cosmetic ingredient derived from its collection of bacterial extracts.Deinove owns a large bacterial collection that includes more than 6,000 rare strains, collected in many different biotopes (hot springs, volcanos, lagoons, beaches and caves) and on various substrates (nearly 600 samples of wood, water, plant, sand, etc.). The company has developed original and patented methods for the selection and culture of these rare bacteria, and several of these strains have been qualified via its cell biology lab according to their properties on different cosmetic activities.
Dow has selected one extract from the bacterial bank, and Deinove will now develop and optimize a dedicated production process and will ensure the industrial transposition and production of the developed cosmetic active, according to Dow. Leveraging its expertise and its cell biology laboratory in Belgium, Dow intends to qualify the cosmetic active and integrate it into its product portfolio, receiving commercial exclusivity worldwide.
“We have chosen Deinove for its widely-recognized expertise in biotechnology and valuation of rare microorganisms. After the launch of AgeCap Smooth in April 2018, this agreement will allow Dow to quickly develop a new natural cosmetic ingredient for our customers. This first collaboration with Deinove is perfectly aligned with our strategy of expanding and transforming our portfolio dedicated to skin care,” said Fabienne Bizeray, Dow’s global strategic marketing leader in skin and sun care.